Mednet Logo
HomeQuestion

Is there a role for Elacestrant in ER+ metastatic breast cancer with ESR1-YAP1 fusion on NGS?

1 Answers
Mednet Member
Mednet Member
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida

It depends on the specific details of the fusion protein and where the fusion breakpoint is. Also, the clonality of the fusion may play a role too. There are reports of a stable in-frame ESR1 e6 YAP1 fusion protein that has the ESR1 DNA binding/nuclear localization domains but the ligand binding dom...

Register or Sign In to see full answer

Is there a role for Elacestrant in ER+ metastatic breast cancer with ESR1-YAP1 fusion on NGS? | Mednet